Aktis Oncology (AKTS) Earnings Date & Reports

Key Takeaways

• Aktis Oncology reported third-quarter fiscal 2026 results on November 12, 2026, for the quarter ended September 30, 2026, missing consensus estimates on both revenue and EPS (earnings per share).
• Collaboration revenue reached $3.9 million, up 147% from $1.6 million a year earlier, but fell short of the roughly $4.1 million consensus forecast.
• Non-GAAP EPS came in at -$0.54, versus a consensus estimate of -$0.49, a $0.05 shortfall driven by sharply higher operating expenses.
• Net loss widened to $29.9 million from $15.5 million a year earlier, as R&D (research and development) spending surged 95% to $32.1 million.
• Cash, cash equivalents, and marketable securities totaled $492.9 million, which management expects to fund the operating plan into 2029.
• For more context, visit these pages to track the company's Major News, Today's Price Move, Price Targets, and Forecast.
• Discover timely, AI-driven trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Aktis Oncology, a clinical-stage radiopharmaceutical company, completed its IPO (initial public offering) in January 2026 and is now advancing a pipeline of targeted radiopharmaceuticals, or radioactive cancer treatments. Because the company is pre-revenue outside of collaboration income, investors focus less on the income statement than on three signals: the pace of its Eli Lilly research collaboration, the rate of cash burn, and clinical trial progress. This quarter matters because it is the first full reporting period since the company's public listing and because rising R&D costs directly shape how far the current cash runway extends, while upcoming trial readouts determine the long-term investment case.

Reported Results

For the quarter ended September 30, 2026, Aktis Oncology reported collaboration revenue of $3.9 million, up from $1.6 million in the prior-year period, reflecting continued advancement of its research collaboration with Eli Lilly and Company. The figure nonetheless came in below the roughly $4.1 million consensus estimate, a shortfall of about 4.7%. Revenue is recognized over time using the cost incurred input method.

On the bottom line, the company posted a net loss of $29.9 million, widening from $15.5 million a year earlier, and a basic and diluted loss per share of $0.54, compared with $19.18 in the prior-year quarter. Non-GAAP EPS of -$0.54 missed the consensus estimate of -$0.49 by $0.05. The wider loss was driven by higher operating expenses, partially offset by increased collaboration revenue and interest income.

Research and development expenses climbed 95% to $32.1 million, reflecting advancement of the AKY-1189 and AKY-2519 clinical trials and higher headcount in clinical development and manufacturing. G&A (general and administrative) expenses rose to $6.5 million from $3.3 million, tied to public-company costs and growth. For the first nine months of fiscal 2026, collaboration revenue was $10.5 million and net loss was $72.4 million.

Cash, cash equivalents, and marketable securities stood at $492.9 million as of September 30, 2026, up from $226.8 million at December 31, 2025, primarily reflecting IPO proceeds. Management expects this balance to fund operations into 2029.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking volatile, event-driven names such as Aktis Oncology, it can offer a faster way to identify comparable setups and monitor shifting momentum across the broader market.

Market Reaction and Investor Sentiment

Aktis Oncology shares traded modestly lower in the session following the release, with the stock down roughly 2.5% intraday, according to market data. The reaction reflects a straightforward interpretation: a revenue and EPS miss, paired with a near-doubling of operating expenses, weighed on sentiment even though the balance sheet remains strong. Investors are balancing two competing narratives. The first is a near $493 million cash position that removes near-term funding risk. The second is a widening loss as the company scales multiple clinical trials, a pattern typical of clinical-stage biopharmaceutical companies but one that requires investors to look past the quarterly miss toward the upcoming data catalysts.

Forward Outlook and Key Factors to Monitor

Looking ahead, the investment narrative for Aktis Oncology will be defined by clinical data rather than quarterly revenue. The company recently initiated a third Phase 1b trial, BActinium-2, evaluating AKY-2519 in non-small cell lung cancer and other tumors expressing the B7-H3 protein target. This expands the company's U.S. footprint across two distinct targets: Nectin-4, addressed by AKY-1189, and B7-H3, addressed by AKY-2519.

The most important near-term catalyst is preliminary data from the NECTINIUM-2 trial of AKY-1189, expected in the first quarter of 2027, followed by initial AKY-2519 results later in 2027. These readouts will be closely watched because they provide the first meaningful clinical validation of the company's radiopharmaceutical platform.

On the financial side, investors should monitor the trajectory of R&D and G&A spending as additional trials enroll patients. While the $492.9 million cash balance supports operations into 2029, consensus forecasts suggest collaboration revenue may moderate in 2027, meaning losses are likely to remain wide. The company's hybrid manufacturing strategy, including its GMP (Good Manufacturing Practice) facility in Boston, is another factor to watch as it positions for later-stage supply.

As with any early-stage biotech, the key risks include clinical setbacks, regulatory hurdles, and execution challenges in scaling manufacturing, all of which could meaningfully affect the outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations